Suchergebnisse - (Standardsuche:ritonavir)

PubPharm (61)

21

Long-Term Results of the Etiotropic Therapy of Subcompensed Liver Cirrhosis in the Outcome of Chronic Hepatitis C

in: Российский журнал гастроэнтерологии, гепатологии, колопроктологии | 2020

von P. O. Bogomolov | A. O. Bueverov | V. E. Bakirova | +4

22

Features of current and intensive therapy of new coronavirus infection in children with comorbidities (clinical cases)

in: Журнал инфектологии | 2020

von K. V. Pshenisnov | Yu. S. Aleksandrovich | V. A. Kaziakhmedov | +2

23

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19

in: Ведомости Научного центра экспертизы средств медицинского применения | 2020

von B. K. Romanov

24

Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method

in: Разработка и регистрация лекарственных средств | 2020

von T. N. Komarov | I. E. Shohin | O. A. Miskiv | +4

25

The virtual screening application for searching potential antiviral agents to treat COVID-19 disease

in: Журнал органічної та фармацевтичної хімії | 2020

von Volodymyr V. Ivanov | Veronika R. Karpina | Svitlana S. Kovalenko | +5

26

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?

in: Качественная клиническая практика | 2020

von Yu. Yu. Kiselev | V. M. Tsvetov | K. B. Mirzaev | +1

27

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C

enthalten in: Terapevticheskii arkhiv | 2019

von Klimova, E. | Burnevich, E. | Chulanov, V. | +9

28

EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION : REAL WORLD DATA

enthalten in: Georgian medical news | 2019

von Zhyvytsia, D. | Tsarova, O. | Skorokhodova, N.

29

The Adverse Drug Reactions Registered During the Postmarketing Period

in: Безопасность и риск фармакотерапии | 2019

von E. V. Shubnikova | M. A. Darmostukova | T. M. Bukatina | +6

30

Monitoring of Foreign Drug Safety Information

in: Безопасность и риск фармакотерапии | 2019

von Editorial article